文献速递神经免疫

共病与多发性硬化疾病活动相关:CombiRx试验发现

Comorbidity is associated with disease activity in MS: Findings from the CombiRx trial.
PubMed 文献 · Neurology · 2020-06-17

该研究对CombiRx临床试验进行二次分析,评估共病与多发性硬化临床和MRI结局的关联。在959名可评估6个月确认残疾恶化的参与者中,55.1%至少有1种共病;焦虑和血脂异常与任何疾病活动风险增加相关,而偏头痛与风险降低相关。

要点

  • 焦虑(HR 1.25)和血脂异常(HR 1.32)增加MS疾病活动风险。
  • 偏头痛与MS疾病活动风险降低相关(HR 0.80)。
  • 临床试验参与者的共病负担可能影响试验结局。

核心结论

  • 共病在MS临床试验参与者中常见,并影响疾病结局包括复发。

研究设计与样本

  • CombiRx临床试验的二次分析,比较干扰素β-1a、醋酸格拉替雷及其联合治疗。
  • 1008名随机参与者中959名(95.1%)符合6个月确认残疾恶化评估条件,中位随访3.4年(范围0.5-6.9年)。

主要发现

  • 入组时55.1%的参与者至少有1种共病。
  • 焦虑(HR 1.25,95%CI 1.01-1.55)和血脂异常(HR 1.32,95%CI 1.01-1.72)与任何疾病活动风险增加相关。
  • 偏头痛(HR 0.80,95%CI 0.67-0.97)与任何疾病活动风险降低相关。

临床怎么用

  • 在MS患者管理中应评估共病,尤其焦虑和血脂异常,可能影响疾病活动。

局限性

  • 共病状态通过病史、合并用药和不良事件确定,可能存在错分。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine whether comorbidity is associated with clinical (relapses, disability worsening) and MRI outcomes in multiple sclerosis (MS) by conducting a secondary analysis of the CombiRx clinical trial. METHODS: CombiRx compared interferon beta-1a, glatiramer acetate, and the combination of these agents. For participants eligible for evaluation of 6-month confirmed disability worsening, we used medical history, concomitant medications, and adverse events to ascertain comorbidity status. Comorbid conditions evaluated included hypertension, dyslipidemia, diabetes mellitus, depression, anxiety disorders, and migraine. Clinical outcomes included disease activity consisting of protocol-defined relapses, disability worsening, and MRI activity. We summarized the prevalence of these comorbid conditions and their association with disease activity and its components using multivariable Cox regression. RESULTS: Of the 1,008 participants randomized, 959 (95.1%) were eligible for assessment of 6-month disability worsening; for this subgroup, the median length of follow-up was 3.4 years (range 0.5-6.9 years). Overall, 55.1% of participants had ≥1 comorbidity at enrollment. After adjustment, anxiety (hazard ratio [HR] 1.25, 95% confidence interval [CI] 1.01-1.55) and dyslipidemia (HR 1.32, 95% CI 1.01-1.72) were associated with an increased hazard of any disease activity, while migraine (HR 0.80, 95% CI 0.67-0.97) was associated with a decreased hazard. CONCLUSIONS: In this large trial population with rigorously obtained outcomes, comorbid conditions were common among participants and influenced disease outcomes, including relapses. The comorbidity burden of clinical trial participants with MS may be an important factor in the outcome of clinical trials. Additional investigations of the impact of comorbidity on clinical trial outcomes and response to disease-modifying therapies are warranted.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Salter A, Kowalec K, Fitzgerald KC, et al. Comorbidity is associated with disease activity in MS: Findings from the CombiRx trial. Neurology. 2020. PMID: 32554770. doi:10.1212/WNL.0000000000010024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。